Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO - Get Free Report) crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.26 and traded as low as $0.25. Northwest Biotherapeutics shares last traded at $0.25, with a volume of 7,608,186 shares.
Northwest Biotherapeutics Stock Up 3.5%
The stock has a market capitalization of $391.98 million, a PE ratio of -4.33 and a beta of -1.14. The firm's fifty day moving average is $0.25 and its 200-day moving average is $0.26.
Northwest Biotherapeutics (OTCMKTS:NWBO - Get Free Report) last posted its quarterly earnings results on Thursday, August 14th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter. The company had revenue of $0.13 million for the quarter.
Northwest Biotherapeutics Company Profile
(
Get Free Report)
Northwest Biotherapeutics, Inc, a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer.
Featured Articles
Before you consider Northwest Biotherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Northwest Biotherapeutics wasn't on the list.
While Northwest Biotherapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
